Expression and clinical significance of apolipoprotein D in male breast cancer and gynaecomastia

British Journal of Surgery

Volumn 86, Issue 9, 1999, Pages 1190-1197

  Serra Diaz C ^a   Vizoso, F ^b   Lamelas, M L ^b   Rodriguez J C ^b   Gonzalez L O ^b   Baltasar, A ^a   Medrano, J ^c  

^a HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

^b HOSPITAL DE JOVE   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN D; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER SURVIVAL; CARCINOMA IN SITU; CONTROLLED STUDY; CORRELATION FUNCTION; FOLLOW UP; GENE EXPRESSION; GYNECOMASTIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LIPID TRANSPORT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALE BREAST; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; APOLIPOPROTEINS; APOLIPOPROTEINS D; BIOLOGICAL MARKERS; BREAST NEOPLASMS, MALE; CARCINOMA IN SITU; DISEASE-FREE SURVIVAL; GYNECOMASTIA; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0032886265     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1999.01157.x     Document Type: Article

References (48)

1. Crichlow RW, Galt SW. Male breast cancer. Surg Clin North Am 1990; 70: 1165-77.
2. Adami H-O, Hakulinen T, Ewertz M, Tretli S, Holmberg L, Karjalainen S. The survival pattern in male breast cancer: an analysis of 1429 patients from the Nordic countries. Cancer 1989; 64: 1177-82.
3. Heller KS, Rosen PP, Schottenfeld D, Ashikari R, Kinne DW. Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg 1978; 188: 60-5.
4. Appelqvist P, Salmo M. Prognosis in carcinoma of the male breast. Acta Chirurgica Scandinavica 1982; 148: 499-502.
5. Ciatto S, Iossa A, Bonardi R, Pacini P. Male breast carcinoma: review of a multicenter series of 150 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Tumori 1990; 76: 555-8.
6. Salvadori B, Saccozzi R, Manzari A, Andreola S, Conti RA, Cusumano F et al. Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer 1994; 30A: 930-5.
7. McConathy WJ, Alaupovic P. Isolation and partial characterization of apolipoprotein D: a new protein moiety of the human plasma lipoprotein system. FEBS Lett 1973; 37: 178-82.
8. Blanco-Vaca F, Via DP, Yang CY, Massey JB, Pownall HJ. Characterization of disulfide-linked heterodimers containing apolipoprotein D in human plasma lipoproteins. J Lipid Res 1992; 33: 1785-96.
9. Albers JJ, Cheung MC, Ewens SL, Tollefson JH. Characterization and immunoassay of apolipoprotein D. Atherosclerosis 1981; 39: 395-409.
10. Francone OL, Gurakar A, Fielding C. Distribution and functions of lecithin : cholesterol acyltransferase and cholesterol ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol. J Biol Chem 1989; 264: 7066-7072.
11. Drayna D, Fielding C, McLean J, Baer B, Castro G, Chen E et al. Cloning and expression of human apolipoprotein D cDNA. J Biol Chem 1986; 261: 16 535-9.
12. Peitsch MC, Boguski MS. Is apolipoprotein D a mammalian bilin-binding protein? New Biol 1990; 2: 197-206.
13. Pearlman WH, Gueriguian JL, Sawyer ME. A specific progesterone-binding component of human breast cyst fluid. J Biol Chem 1973; 248: 5736-41.
14. Pearlman WH, Peng LH, Mazoujian G, Haagensen DE Jr, Wells SA Jr, Kister SJ. A specific progesterone-binding component of human breast cyst fluid: its isolation and characterization (proceedings). J Endocrinol 1977; 75: 19-20P.
15. Silva JS, Cox CE, Wells SA Jr, Paul D, Dilley WG, McCarty KS Sr et al. Biochemical correlates of morphologic differentiation in human breast cancer. Surgery 1982; 92: 443-9
16. Dilley WG, Haagensen DE, Cox CE, Wells SA Jr. Immunologic and steroid binding properties of the GCDFP-24 protein, isolated from human breast gross cystic disease fluid. Breast Cancer Res Treat 1990; 16: 253-60.
17. Balbín M, Freije JMP, Fueyo A, Sánchez LM, López-Otín C. Apolipoprotein D is the major protein component in cyst fluid from women with human breast gross cystic disease. Biochem J 1990; 271: 803-7.
18. Simard J, Dauvois S, Haagensen DE, Lévesque C, Mérand Y, Labrie F. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endocrinology 1990; 126: 3223-31.
19. Simard J, Veilleux R, de Launoit Y, Haagensen DE, Labrie F. Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells. Cancer Res 1991; 51: 4336-41.
20. Simard J, De Launolt Y, Haagensen DE, Labrie F. Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein D messenger ribonucleic acid levels and secretion in human breast cancer cells. Endocrinology 1992; 130: 1115-21.
21. Haagensen DE, Stewart P, Dilley WG, Wells SA. Secretion of breast gross cystic disease fluid proteins by T47 D breast cancer cells in culture: modulation by steroid hormones. Breast Cancer Res Treat 1992; 23: 77-86.
22. Provost PR, Marcel YL, Milne RW, Weech PK, Rassart E. Apolipoprotein D transcription occurs specifically in nonproliferating quiescent and senescent fibroblast cultures. FEBS Lett 1991; 290: 139-41.
23. Mazoujian G, Haagensen DE. The immunopathology of gross cystic disease fluid proteins. Ann NY Acad Sci 1990; 586: 188-97.
24. Hall RE, Aspinall JO, Horsfall D, Birrell SN, Bentel JM, Sutherland RL et al. Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. Br J Cancer 1996; 74: 1175-80.
25. Zhang SX, Bentel JM, Ricciardelli C, Horsfall DJ, Haagensen DF, Marshall VR et al. Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers. J Urol 1998; 159: 548-54.
26. Hall RE, Clements JA, Birrell SN, Tilley WD. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer 1998; 78: 360-5.
27. Díez-Itza I, Vizoso F, Merino AM, Sánchez LM, Tolivia J, Fernández J et al. Expression and prognostic significance of apolipoprotein D in breast cancer. Am J Pathol 1994; 144: 310-20.
28. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-77.
29. Balbín M, Vizoso F, Sánchez LM, Venta R, Ruibal A, Fueyo A et al. GCDFP-70 protein in fluid identified as albumin and used to classify cysts in women with breast gross cystic disease. Clin Chem 1991; 37: 547-51.
30. Vaitukaitis JL. Production of antisera with small doses of immunogen: multiple intradermal injections. Methods Enzymol 1981; 73: 46-52.
31. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986; 46(Suppl 8): 4244-8s.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
33. Mantel M, Myers M. Problems of convergence of maximum likelihood iterative procedures in multiparameter situations. J Am Stat Assoc 1971; 66: 484-91.
34. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-220.
35. Dixon WJ, Brown MB, eds. BMDP Statistical Software. Berkeley, California: University of California Press, 1983.
36. Braunstein GD. Gynecomastia. N Engl J Med 1993; 328: 490-5.
37. Sorelde JA, Lea OA, Kvinnsland S. Progesterone-binding cyst protein (PBCP=GCDFP-24) and steroid hormone receptors as markers of differentiation in breast cancer. Inverse relation of distribution in normal and malignant tissue of the same breast. Anticancer Res 1991; 11: 1323-6.
38. Sánchez LM, Vizoso F, Díez-Itza I, López-Otín C. Identification of the major protein components in breast secretions from women with benign and malignant breast diseases. Cancer Res 1992; 52: 95-100.
39. Aspinall JO, Bentel JM, Horsfall DJ, Haagensen DF, Marshall VR, Tilley WD. Differential expression of apolipoprotein D and prostate specific antigen in benign and malignant prostate tissues. J Urol 1995, 154: 622-8.
40. Morgan MB, Pitha JV. Myofibroblastoma of the breast revisited: an etiologic association with androgens? Hum Pathol 1998; 29: 347-51.
41. Serra C, Vizoso F, Rodriguez JC, Merino AM, González LO, Baltasar A et al. Expression of pepsinogen C in gynecomastias and male breast carcinomas. World J Surg 1999; 23: 439-45.
42. Beato M. Gene regulation by steroid hormones. Cell 1989; 56: 335-44.
43. Marugo M, Bernasconi D, Miglietta L, Fazzuoli L, Ravera F, Cassulo S et al. Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T). J Steroid Biochem Mol Biol 1992; 42: 547-54.
44. Hall RE, Birrell SN, Tilley WD, Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. Eur J Cancer 1994; 30: 484-90.
45. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MSA, Horsfall DJ et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995; 52: 459-67.
46. Berger FG, Watson C. Androgen-regulated gene expression. Annu Rev Physiol 1989; 51: 51-65.
47. Kuenen-Boumeester V, Van der Kwast JJ, Claassen CC, Look MP, Liem GS, Klijn JGM et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 1996; 32A: 1560-5.
48. Weber-Chappuis K, Bieri-Burger S, Hurlimann J. Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer 1996; 32A: 1686-92.